子宮内膜癌治療の世界市場：2025年

子宮内膜癌治療の市場規模は今後数年で急成長が見込まれます。CAGR 6.3％で推移し、2029年には416億4,000万米ドルに成長すると予測されています。

予測期間の成長は、子宮内膜癌の罹患率の上昇、個別化医療アプローチ、免疫療法の進歩、標的療法の拡大、政府の取り組み、資金調達などに起因すると考えられています。予測期間の主な動向には、ホルモン療法の開発、治療計画におけるAIの導入、新規化学療法剤の探索、支持療法の強化、新興療法の臨床試験などが含まれます。

子宮内膜癌治療市場の成長は、子宮内膜癌の有病率の増加によって牽引されると予想されています。この急増は、危険因子の変化、検出・診断法の改善、意識の向上、高齢化などに起因します。子宮内膜癌治療は、早期発見、標的治療の提供、再発予防、治療の選択肢を増やすための臨床試験や調査研究への貢献において重要な役割を果たしています。子宮内膜癌の有病率の継続的な上昇と治療オプションの継続的な進歩により、子宮内膜癌治療市場は成長の示す見通しです。Cancer.Netは、2023年に米国で約6万6,200人が子宮体癌または子宮内膜癌と診断されたと推計しています。これらのことから、子宮内膜癌の有病率の増加が子宮内膜癌治療市場の主要な促進要因となっています。

個別化医療への焦点も子宮内膜癌治療市場の成長を促進しています。個別化医療とは、個人の遺伝子やタンパク質関連の情報に基づいて、病気を予防、発見、治療するための薬を調整することです。子宮内膜癌の治療において、個別化医療は腫瘍の遺伝子構成を分析するためにゲノムプロファイリングを利用します。このアプローチは、治療決定の指針となる特定の突然変異、変化、バイオマーカーの同定を容易にします。Personalized Medicine Coalitionによれば、FDAは2022年に新たに承認される分子生物学的治療薬全体の約34％を占める12の個別化医療薬を承認しました。これらのことから、個別化医療への注目の高まりも子宮内膜癌治療市場の成長の重要な促進要因となっています。

当レポートでは、世界の子宮内膜癌治療の市場を調査し、市場概要・特徴、主要動向、市場影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 子宮内膜癌治療市場：特徴

第3章 子宮内膜癌治療市場：動向・戦略

第4章 子宮内膜癌治療市場：マクロ経済シナリオ (金利、インフレ、地政学、COVID-19とその回復が市場に与える影響を含む)

第5章 世界の子宮内膜癌治療市場：成長分析・戦略分析フレームワーク

• PESTEL分析・成長推進因子/阻害因子
• エンドユーザー産業の分析
• 市場成長率の分析
• 市場規模の推移・成長率
• 市場規模の成長予測
• TAM (Total Addressable Market) 市場

第6章 子宮内膜癌治療市場：セグメンテーション

• 市場規模の推移・予測：タイプ別
• 腺癌
• 子宮癌肉腫
• 扁平上皮癌
• 小細胞癌
• 移行性癌
• 漿液性癌
• その他
• 市場規模の推移・予測：診断方法別
• 生検
• 骨盤超音波検査
• 子宮鏡検査
• CTスキャン
• その他
• 市場規模の推移・予測：投与経路別
• 経口
• 静脈内
• 市場規模の推移・予測：流通チャネル別
• 病院薬局
• 小売薬局
• オンライン薬局
• 市場規模の推移・予測：腺癌のサブタイプ別
• 類内膜腺癌
• 非類内膜腺癌
• 市場規模の推移・予測：子宮癌肉腫のサブタイプ別
• 高悪性度子宮癌肉腫
• 低悪性度子宮癌肉腫
• 市場規模の推移・予測：扁平上皮癌のサブタイプ別
• 角化扁平上皮癌
• 非角化性扁平上皮癌
• 市場規模の推移・予測：小細胞癌のサブタイプ別
• 小細胞神経内分泌癌
• 市場規模の推移・予測：移行性癌のサブタイプ別
• 子宮の移行上皮癌
• 市場規模の推移・予測：漿液性癌のサブタイプ別
• 高悪性度漿液性癌
• 低悪性度漿液性癌
• 市場規模の推移・予測：その他のタイプのサブタイプ別
• 混合細胞型癌
• 未分化癌
• その他の稀な組織学的タイプ

第7章 子宮内膜癌治療市場：地域・国別分析

• 市場規模の推移・予測：地域別
• 市場規模の推移・予測：国別

第8章 アジア太平洋の子宮内膜癌治療市場

第9章 中国の子宮内膜癌治療市場

第10章 インドの子宮内膜癌治療市場

第11章 日本の子宮内膜癌治療市場

第12章 オーストラリアの子宮内膜癌治療市場

第13章 インドネシアの子宮内膜癌治療市場

第14章 韓国の子宮内膜癌治療市場

第15章 西欧の子宮内膜癌治療市場

第16章 英国の子宮内膜癌治療市場

第17章 ドイツの子宮内膜癌治療市場

第18章 フランスの子宮内膜癌治療市場

第19章 イタリアの子宮内膜癌治療市場

第20章 スペインの子宮内膜癌治療市場

第21章 東欧の子宮内膜癌治療市場

第22章 ロシアの子宮内膜癌治療市場

第23章 北米の子宮内膜癌治療市場

第24章 米国の子宮内膜癌治療市場

第25章 カナダの子宮内膜癌治療市場

第26章 南米の子宮内膜癌治療市場

第27章 ブラジルの子宮内膜癌治療市場

第28章 中東の子宮内膜癌治療市場

第29章 アフリカの子宮内膜癌治療市場

第30章 子宮内膜癌治療市場：競合情勢と企業プロファイル

• 競合情勢
• 企業プロファイル
  • Abbott Laboratories
  • Novartis AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG
  • Merck &Co. Inc.

第31章 子宮内膜癌治療市場：その他の大手および革新的企業

• Sanofi-Aventis
• Becton Dickinson And Company
• Teva Pharmaceutical Industries Limited
• AstraZeneca plc
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Eisai Co. Ltd.
• AbbVie Inc.
• Roche Holding AG
• Janssen Biotech Inc.
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Bayer AG
• Eli Lilly and Company
• Varian Medical Systems Inc.

第32章 世界の子宮内膜癌治療市場：競合ベンチマーキングとダッシュボード

第33章 子宮内膜癌治療市場：主要M&A

第34章 子宮内膜癌治療市場：最近の動向

第35章 子宮内膜癌治療市場：潜在性の高い国・セグメント・戦略

• 最も新しい機会を提供する国
• 最も新しい機会を提供するセグメント
• 成長戦略

第36章 付録

Endometrial cancer treatment involves medical interventions aimed at managing and potentially curing cancer that develops in the lining of the uterus.

The main types of endometrial cancer include adenocarcinoma, uterine carcinosarcoma, squamous cell carcinoma, small cell carcinoma, transitional carcinoma, serous carcinoma, and other types. Adenocarcinoma refers to a type of cancer that originates in the glandular cells of a particular organ or tissue in the body. The treatment for endometrial cancer, specifically adenocarcinoma, involves various approaches such as surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, or a combination of these methods. Diagnosing endometrial cancer may include procedures such as biopsy, pelvic ultrasound, hysteroscopy, CT scan, and other diagnostic methods. The endometrial cancer treatments can be administered orally or intravenously, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The endometrial cancer treatment market research report is one of a series of new reports from The Business Research Company that provides endometrial cancer treatment market statistics, including endometrial cancer treatment industry global market size, regional shares, competitors with an endometrial cancer treatment market share, detailed endometrial cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the endometrial cancer treatment industry. This endometrial cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endometrial cancer treatment market size has grown steadily in recent years. It will grow from$31.04 billion in 2024 to $32.55 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to demographic trends, advancements in diagnostic tools, treatment guidelines and protocols, awareness and screening programs, and the evolution of healthcare infrastructure

The endometrial cancer treatment market size is expected to see strong growth in the next few years. It will grow to $41.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the rising incidence of endometrial cancer, personalized medicine approaches, immunotherapy advancements, expanding targeted therapies, government initiatives and funding. Major trends in the forecast period include the development of hormone therapies, implementation of artificial intelligence (AI) in treatment planning, exploration of novel chemotherapeutic agents, enhanced supportive care, and clinical trials for emerging therapies.

The anticipated growth of the endometrial cancer treatment market is expected to be driven by the growing prevalence of endometrial cancer. The term "prevalence of endometrial cancer" denotes the increasing number of cases of endometrial cancer within a specific population or over a certain period. This surge is attributed to changes in risk factors, improved detection and diagnosis methods, increased awareness, and an aging population. Endometrial cancer treatments play a crucial role in early detection, offering targeted therapies, preventing recurrence, and contributing to clinical trials and research studies to enhance treatment options. With the continuous rise in the prevalence of endometrial cancer and ongoing advancements in treatment options, the endometrial cancer treatment market is poised for growth. As an illustration, Cancer.Net estimates that around 66,200 people in the United States will be diagnosed with uterine or endometrial cancer in 2023. Hence, the increasing prevalence of endometrial cancer is a key driver of the endometrial cancer treatment market.

The emphasis on personalized medicine is set to fuel the growth of the endometrial cancer treatment market. Personalized medicine involves tailoring medication to prevent, detect, or treat diseases based on an individual's genetic or protein-related information. In the context of endometrial cancer treatment, personalized medicine utilizes genomic profiling to analyze the genetic composition of tumors. This approach facilitates the identification of specific mutations, alterations, or biomarkers that guide treatment decisions. Notably, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities in 2022, according to the Personalized Medicine Coalition. Therefore, the increasing focus on personalized medicine serves as a significant driver for the growth of the endometrial cancer treatment market.

Technological advancements in endometrial cancer diagnosis and treatment are a key trend gaining popularity in the endometrial cancer treatment market. Companies operating in the market are launching technologically advanced endometrial cancer diagnoses and treatments to sustain their position in the market. For instance, in April 2022, Roche Holding AG received FDA approval for VENTANA MMR RxDx Panel endometrial cancer diagnostic kit to diagnose patients eligible for anti-PD1 immunotherapy that is treatment with JEMPERLI (dostarlimab-gxly) monotherapy. This test is an effective tool for clinicians for patient diagnosis and providing new treatment options to women having MMR-deficient endometrial cancer during or after chemotherapy treatment.

Key players in the endometrial cancer treatment market are concentrating on developing innovative drug solutions to enhance patient outcomes and meet unmet medical needs. These cutting-edge treatments focus on targeted therapies, immunotherapies, and personalized medicine approaches to improve effectiveness while reducing side effects. For example, in March 2022, Merck & Co. Inc., a US-based pharmaceutical company, obtained approval from the US Food and Drug Administration (FDA) for KEYTRUDA, Merck's anti-PD-1 therapy, which serves as a standalone treatment for patients with advanced endometrial carcinoma that is characterized by microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR).

In February 2024, Novartis AG, a pharmaceutical company based in Switzerland, acquired MorphoSys for $2.9 billion. This acquisition allows Novartis to gain access to innovative treatments, particularly pelabresib (CPI-0610), which is currently in development for myelofibrosis, a rare type of blood cancer. MorphoSys AG is a biopharmaceutical company located in Germany that focuses on developing cutting-edge medicines in the field of oncology.

Major companies operating in the endometrial cancer treatment market include Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi-Aventis, Becton Dickinson And Company, Teva Pharmaceutical Industries Limited, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co. Ltd., AbbVie Inc., Roche Holding AG, Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eli Lilly and Company, Varian Medical Systems Inc., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Stemline Therapeutics Inc., Syros Pharmaceuticals Inc., Novocure Ltd.

North America was the largest region in the endometrial cancer treatment market in 2024. Asia-pacific is expected to be the fastest-growing region in the global endometrial cancer treatment market report during the forecast period. The regions covered in the endometrial cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the endometrial cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The endometrial treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of endometrial cancer. The endometrial treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endometrial Cancer Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on endometrial cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for endometrial cancer treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endometrial cancer treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Adenocarcinoma; Uterine Carcinosarcoma; Squamous Cell Carcinoma; Small Cell Carcinoma; Transitional Carcinoma; Serous Carcinoma; Other Types
• 2) By Diagnosis Method: Biopsy; Pelvic Ultrasound; Hysteroscopy; CT Scan; Other Diagnosis Methods
• 3) By Route Of Administration: Oral; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Adenocarcinoma: Endometrioid Adenocarcinoma; Non-Endometrioid Adenocarcinoma
• 2) By Uterine Carcinosarcoma: High-Grade Uterine Carcinosarcoma; Low-Grade Uterine Carcinosarcoma
• 3) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma
• 4) By Small Cell Carcinoma: Small Cell Neuroendocrine Carcinoma
• 5) By Transitional Carcinoma: Transitional Cell Carcinoma Of The Uterus
• 6) By Serous Carcinoma: High-Grade Serous Carcinoma; Low-Grade Serous Carcinoma
• 7) By Other Types: Mixed Cell Type Carcinomas; Undifferentiated Carcinoma; Other Rare Histological Types
• Companies Mentioned: Abbott Laboratories; Novartis AG; GlaxoSmithKline plc; F. Hoffmann-La Roche AG; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Endometrial Cancer Treatment Market Characteristics

3. Endometrial Cancer Treatment Market Trends And Strategies

4. Endometrial Cancer Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Endometrial Cancer Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Endometrial Cancer Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Endometrial Cancer Treatment Market Growth Rate Analysis
• 5.4. Global Endometrial Cancer Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Endometrial Cancer Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Endometrial Cancer Treatment Total Addressable Market (TAM)

6. Endometrial Cancer Treatment Market Segmentation

• 6.1. Global Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Uterine Carcinosarcoma
• Squamous Cell Carcinoma
• Small Cell Carcinoma
• Transitional Carcinoma
• Serous Carcinoma
• Other Types
• 6.2. Global Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods
• 6.3. Global Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.4. Global Endometrial Cancer Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endometrioid Adenocarcinoma
• Non-Endometrioid Adenocarcinoma
• 6.6. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Uterine Carcinosarcoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Grade Uterine Carcinosarcoma
• Low-Grade Uterine Carcinosarcoma
• 6.7. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Keratinizing Squamous Cell Carcinoma
• Non-Keratinizing Squamous Cell Carcinoma
• 6.8. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Small Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Cell Neuroendocrine Carcinoma
• 6.9. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Transitional Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transitional Cell Carcinoma Of The Uterus
• 6.10. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Serous Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Grade Serous Carcinoma
• Low-Grade Serous Carcinoma
• 6.11. Global Endometrial Cancer Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Cell Type Carcinomas
• Undifferentiated Carcinoma
• Other Rare Histological Types

7. Endometrial Cancer Treatment Market Regional And Country Analysis

• 7.1. Global Endometrial Cancer Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Endometrial Cancer Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Endometrial Cancer Treatment Market

• 8.1. Asia-Pacific Endometrial Cancer Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Endometrial Cancer Treatment Market

• 9.1. China Endometrial Cancer Treatment Market Overview
• 9.2. China Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Endometrial Cancer Treatment Market

• 10.1. India Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Endometrial Cancer Treatment Market

• 11.1. Japan Endometrial Cancer Treatment Market Overview
• 11.2. Japan Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Endometrial Cancer Treatment Market

• 12.1. Australia Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Endometrial Cancer Treatment Market

• 13.1. Indonesia Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Endometrial Cancer Treatment Market

• 14.1. South Korea Endometrial Cancer Treatment Market Overview
• 14.2. South Korea Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Endometrial Cancer Treatment Market

• 15.1. Western Europe Endometrial Cancer Treatment Market Overview
• 15.2. Western Europe Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Endometrial Cancer Treatment Market

• 16.1. UK Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Endometrial Cancer Treatment Market

• 17.1. Germany Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Endometrial Cancer Treatment Market

• 18.1. France Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Endometrial Cancer Treatment Market

• 19.1. Italy Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Endometrial Cancer Treatment Market

• 20.1. Spain Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Endometrial Cancer Treatment Market

• 21.1. Eastern Europe Endometrial Cancer Treatment Market Overview
• 21.2. Eastern Europe Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Endometrial Cancer Treatment Market

• 22.1. Russia Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Endometrial Cancer Treatment Market

• 23.1. North America Endometrial Cancer Treatment Market Overview
• 23.2. North America Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Endometrial Cancer Treatment Market

• 24.1. USA Endometrial Cancer Treatment Market Overview
• 24.2. USA Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Endometrial Cancer Treatment Market

• 25.1. Canada Endometrial Cancer Treatment Market Overview
• 25.2. Canada Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Endometrial Cancer Treatment Market

• 26.1. South America Endometrial Cancer Treatment Market Overview
• 26.2. South America Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Endometrial Cancer Treatment Market

• 27.1. Brazil Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Endometrial Cancer Treatment Market

• 28.1. Middle East Endometrial Cancer Treatment Market Overview
• 28.2. Middle East Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Endometrial Cancer Treatment Market

• 29.1. Africa Endometrial Cancer Treatment Market Overview
• 29.2. Africa Endometrial Cancer Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Endometrial Cancer Treatment Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Endometrial Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Endometrial Cancer Treatment Market Competitive Landscape And Company Profiles

• 30.1. Endometrial Cancer Treatment Market Competitive Landscape
• 30.2. Endometrial Cancer Treatment Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Endometrial Cancer Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi-Aventis
• 31.2. Becton Dickinson And Company
• 31.3. Teva Pharmaceutical Industries Limited
• 31.4. AstraZeneca plc
• 31.5. Pfizer Inc.
• 31.6. Bristol-Myers Squibb Company
• 31.7. Eisai Co. Ltd.
• 31.8. AbbVie Inc.
• 31.9. Roche Holding AG
• 31.10. Janssen Biotech Inc.
• 31.11. Takeda Pharmaceutical Company Limited
• 31.12. Amgen Inc.
• 31.13. Bayer AG
• 31.14. Eli Lilly and Company
• 31.15. Varian Medical Systems Inc.

32. Global Endometrial Cancer Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Endometrial Cancer Treatment Market

34. Recent Developments In The Endometrial Cancer Treatment Market

35. Endometrial Cancer Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Endometrial Cancer Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Endometrial Cancer Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Endometrial Cancer Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer